Publications

How I Treat Metastatic Pancreatic Cancer With Emerging Therapies

BA Krantz, EM O’Reilly

HOW RELEVANT IS PRE-OPERATIVE OBSTRUCTIVE SLEEP APNEA IN THE ASYMPTOMATIC BARIATRIC SURGICAL PATIENT? Perioperative management

E O'reilly, H Shabana, C O'boyle, L Doherty

Immune Therapy for Liver Cancers

Hilmi M, Vienot A, Rousseau B, Neuzillet C

Improving Health Outcomes in Pancreatic Cancer Using Animated Pancreas Patient (APP) Visual Formats of Learning: A National Pancreas Foundation (NPF) Patient Education Initiative

S Munigala, EM O'Reilly, M Alsante, JM Holt, AH Ko, A Gelrud

KRAS and TP53 status as a predictor of survival in patients with resected pancreatic ductal adenocarcinoma.

CA McIntyre, SA Lawrence, W Wong, JF Chou, M Capanu, MF Berger, ...

Long-Term Follow-up of FOLFIRINOX Induction Therapy for Locally Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)

N Cohen, CA McIntyre, DA Goldman, G Mithat, E Sadot, E O'Reilly, ...

Longitudinal follow-up of a prospective phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma reveals distinct patterns …

J Datta, CA McIntyre, J Chou, G Askan, JA Drebin, M Capanu, ...

MA07. 02 early change of dNLR is correlated with outcomes in advanced NSCLC patients treated with immunotherapy

L Mezquita, I Preeshagul, E Auclin, D Saravia, L Hendriks, H Rizvi, ...

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ...

Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer

A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...

Mid and distal gastric cancers

LE Harrison, EM O’Reilly, BD Minsky, GK Schwartz, MS Karpeh Jr

NCCN guidelines insights: pancreatic adenocarcinoma, version 1.2019: featured updates to the NCCN guidelines

MA Tempero, MP Malafa, EG Chiorean, B Czito, C Scaife, AK Narang, ...

Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC …

HL Kindler, P Hammel, M Reni, E Van Cutsem, TM Mercade, MJ Hall, ...

Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC …

DY Oh, T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ...

Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, M Hall, J Park, ...

On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).

AJ Hatch, FS Ou, T Zemla, MD Starr, JC Brady, Y Liu, F Innocenti, ...

Pancreas cancer‐associated weight loss

AE Hendifar, MQB Petzel, TA Zimmers, CS Denlinger, LM Matrisian, ...

Pancreatic cancer-A disease in need: Optimizing and integrating supportive care

Moffat GT, Epstein AS, O'Reilly EM

Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial: AC Wei et al.

AC Wei, FS Ou, Q Shi, X Carrero, EM O’Reilly, J Meyerhardt, RA Wolff, ...

Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer

Park W, Lopes G

Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected …

MA Tempero, M Reni, H Riess, EM O’Reilly, S Krishnamurthi, P Österlund, ...

Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).

BA Krantz, E Gedvilaite, JF Chou, M Capanu, D You, KH Yu, ...

POLO: health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

P Hammel, HL Kindler, M Reni, E Van Cutsem, TM Mercade, MJ Hall, ...

POLO: time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic …

E Van Cutsem, T Golan, P Hammel, M Reni, T Macarulla, MJ Hall, ...

Prognostic value of the Memorial Sloan Kettering (MSK) prognostic score (MPS) in pancreatic ductal adenocarcinoma (PDAC).

J Lebenthal, J Zheng, PA Glare, EM O'Reilly, AS Epstein

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

EK Bergsland, MR Mahoney, TR Asmis, N Hall, P Kumthekar, ...

randomized trial of adjuvant</i> nab<//i>-paclitaxel plus gemcitabine (</i> nab<//i>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

MA Tempero, M Reni, H Riess, U Pelzer, EM O'Reilly, JM Winter, DY Oh, ...

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC …

FA Sinicrope, FS Ou, T Zemla, AB Nixon, K Mody, A Levasseur, AC Dueck, ...

Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations

RR Narayan, JM Creasy, DA Goldman, M Gönen, C Kandoth, R Kundra, ...

Retooling a blood-based biomarker: phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immuno-PET imaging of pancreatic cancer

C Lohrmann, EM O'Reilly, JA O'Donoghue, N Pandit-Taskar, ...

Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer

AA Khorana, GA Soff, AK Kakkar, S Vadhan-Raj, H Riess, T Wun, ...

Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.

S Vadhan-Raj, MG McNamara, M Venerito, H Riess, EM O'Reilly, ...

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, et al.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, …

Tumour lineage shapes BRCA-mediated phenotypes

P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, ...

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

EM O’reilly, JF Hechtman

We wish to thank the following reviewers for their generous assistance in evaluating manuscripts submitted to JNCI Cancer Spectrum during the past year.

C Annunziata, M Anurag, B Arun, P Bach, W Barlow, T Bekaii-Saab, ...

(P09) Combined Use of Radiosurgery With Concurrent PD-1/PD-L1 Inhibition For Metastatic Brain Lesions of NSCLC

G Azzam, W Park, E Mellon, A Markoe, N Elsayyad, G Lopes, ...

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

JJ Harding, RK Do, IE Dika, E Hollywood, K Uhlitskykh, E Valentino, ...

A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

J Rodon Ahnert, MH Taylor, EM O'Reilly, J Zhang, RC Doebele, Y Ben, ...

A phase II study of pre-and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC …

AC Wei, FS Ou, Q Shi, EM O'Reilly, JA Meyerhardt, RA Wolff, HL Kindler, ...

A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).

BA Wilky, MM Trucco, D Kolonias, E Wieder, T Subhawong, A Rosenberg, ...

A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis

K Yu, S Mantha, C Tjan, E Kaufmann, RB Brenner, M Lowery, G Ku, N Raj, ...

A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

EM O'Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, GA Fisher, ...

A randomized trial of acceptability and effects of values-based advance care planning in outpatient oncology: person-centered oncologic care and choices

AS Epstein, EM O'Reilly, E Shuk, D Romano, Y Li, W Breitbart, ...

AB098. P072. Investigation of BRCAness in pancreatic cancer using patient-derived organoid models

N Lecomte, MA Al Efishat, G Askan, R Wang, MF Attiyeh, PBC Albornoz, ...

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab …

EM O'Reilly, JSZ Wang, KH Yu, MA Lowery, AM Varghese, JC Bendell, ...

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM

ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).

JJ Harding, RKG Do, E Hollywood, K Uhlitskykh, E Valentino, PJ Wan, ...

An inflammation paradox: Obesity vs. neutrophil-lymphocyte ratio in immunotherapy

W Park, V Florou, A Torres, D Saravia, S Algaze, G Lopes, ...